Oral Presentation ESA-SRB-ANZOS 2025 in conjunction with ENSA

Clues to the underlying pathophysiology of low-renin hypertension using steroid profiling (128441)

Sonali S Shah 1 , Muhammad Akram 1 , Graeme Eisenhofer 2 , Peter J Fuller 1 , Morag J Young 1 , Jun Yang 1
  1. Centre for Endocrinology and Reproductive Health, Hudson Institute of Medical Research, Clayton, VIC , Australia
  2. Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Publish consent withheld
  1. 1. Shah SS, Libianto R, Gwini SM, Rusell G, Young MJ, Fuller PJ, Yang J. Prevalence and Characteristics of Low-renin Hypertension in a Primary Care Population. J Endocr Soc. 2024;8:bvae113. doi: 10.1210/jendso/bvae113
  2. 2. Shah SS, Zhang J, Gwini SM, Young MJ, Fuller PJ, Yang J. Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. J Hum Hypertens. 2024;38:383-392. doi: 10.1038/s41371-023-00891-1
  3. 3. Eisenhofer G, Kurlbaum M, Peitzsch M, Constantinescu G, Remde H, Schulze M, Kaden D, Muller LM, Fuss CT, Kunz S, et al. The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. The Journal of clinical endocrinology and metabolism. 2022;107:e2027-e2036. doi: 10.1210/clinem/dgab924